Allison Kanakis1, Kishore Vipperla2, Georgios I Papachristou2, Randall E Brand2, Adam Slivka2, David C Whitcomb3, Dhiraj Yadav4. 1. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 2. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 3. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Department of Cell Biology and Physiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA. 4. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: yadavd@upmc.edu.
Abstract
BACKGROUND: Chronic pancreatitis (CP) patients have a high prevalence of osteoporotic fractures. In addition to prevalence of osteoporotic fractures, we evaluated how often bone health is assessed by dual-energy x-ray absorptiometry (DXA) in clinical practice, and the performance of Fracture Risk Assessment Tool (FRAX®) in predicting fracture risk in CP patients. METHODS: Medical records of CP patients age ≥40 years prospectively enrolled in the North American Pancreatitis Study 2 (NAPS2) from the University of Pittsburgh Medical Center from 2000 to 2014 were retrospectively reviewed to gather additional relevant data before, at, and after enrollment until December 2016. We determined if patients underwent DXA, compared their observed prevalence of fractures with published data from two large US studies based on administrative data, and their predicted fracture risk with US population based on FRAX®. RESULTS: Only 21% (49/239) patients were evaluated by DXA during their care. The observed cumulative prevalence of fragility fractures in NAPS2 CP patients (9.2%, 95% confidence interval 5.9-13.6) was significantly greater than in controls (1.46% and 2.16%, p ≤ 0.001 for each comparison) and CP patients (4.66%, and 5.13%, p < 0.005 for each comparison) in the two US administrative data studies. The FRAX® 10-year probability of major osteoporotic fracture of ≥20% (5.1% vs. 8.3%, p > 0.05) and for hip fracture of ≥3% (19.6% vs. 18.9%, p > 0.05) in NAPS2 CP patients did not differ from the US population. CONCLUSIONS: Despite their high risk of fragility fractures, bone health is infrequently assessed in CP patients. FRAX® may not adequately predict fracture risk in CP patients.
BACKGROUND: Chronic pancreatitis (CP) patients have a high prevalence of osteoporotic fractures. In addition to prevalence of osteoporotic fractures, we evaluated how often bone health is assessed by dual-energy x-ray absorptiometry (DXA) in clinical practice, and the performance of Fracture Risk Assessment Tool (FRAX®) in predicting fracture risk in CP patients. METHODS: Medical records of CP patients age ≥40 years prospectively enrolled in the North American Pancreatitis Study 2 (NAPS2) from the University of Pittsburgh Medical Center from 2000 to 2014 were retrospectively reviewed to gather additional relevant data before, at, and after enrollment until December 2016. We determined if patients underwent DXA, compared their observed prevalence of fractures with published data from two large US studies based on administrative data, and their predicted fracture risk with US population based on FRAX®. RESULTS: Only 21% (49/239) patients were evaluated by DXA during their care. The observed cumulative prevalence of fragility fractures in NAPS2 CP patients (9.2%, 95% confidence interval 5.9-13.6) was significantly greater than in controls (1.46% and 2.16%, p ≤ 0.001 for each comparison) and CP patients (4.66%, and 5.13%, p < 0.005 for each comparison) in the two US administrative data studies. The FRAX® 10-year probability of major osteoporotic fracture of ≥20% (5.1% vs. 8.3%, p > 0.05) and for hip fracture of ≥3% (19.6% vs. 18.9%, p > 0.05) in NAPS2 CP patients did not differ from the US population. CONCLUSIONS: Despite their high risk of fragility fractures, bone health is infrequently assessed in CP patients. FRAX® may not adequately predict fracture risk in CP patients.
Authors: Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak Journal: Endocr Pract Date: 2010 Nov-Dec Impact factor: 3.443
Authors: Marianna Arvanitakis; Johann Ockenga; Mihailo Bezmarevic; Luca Gianotti; Željko Krznarić; Dileep N Lobo; Christian Löser; Christian Madl; Remy Meier; Mary Phillips; Henrik Højgaard Rasmussen; Jeanin E Van Hooft; Stephan C Bischoff Journal: Clin Nutr Date: 2020-01-22 Impact factor: 7.324
Authors: Sinead N Duggan; Christina Purcell; Mark Kilbane; Myra O'Keane; Malachi McKenna; Peter Gaffney; Paul F Ridgway; Gerard Boran; Kevin C Conlon Journal: Am J Gastroenterol Date: 2015-01-27 Impact factor: 10.864
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: C Mel Wilcox; Bimaljit S Sandhu; Vikesh Singh; Andres Gelrud; Judah N Abberbock; Stuart Sherman; Gregory A Cote; Samer Al-Kaade; Michelle A Anderson; Timothy B Gardner; Michele D Lewis; Christopher E Forsmark; Nalini M Guda; Joseph Romagnuolo; John Baillie; Stephen T Amann; Thiruvengadam Muniraj; Gong Tang; Darwin L Conwell; Peter A Banks; Randall E Brand; Adam Slivka; David Whitcomb; Dhiraj Yadav Journal: Am J Gastroenterol Date: 2016-08-16 Impact factor: 10.864
Authors: E S Siris; R Adler; J Bilezikian; M Bolognese; B Dawson-Hughes; M J Favus; S T Harris; S M Jan de Beur; S Khosla; N E Lane; R Lindsay; A D Nana; E S Orwoll; K Saag; S Silverman; N B Watts Journal: Osteoporos Int Date: 2014-02-28 Impact factor: 4.507
Authors: Phil A Hart; Dhiraj Yadav; Liang Li; Savi Appana; William Fisher; Evan Fogel; Chris E Forsmark; Walter G Park; Stephen Pandol; Mark D Topazian; Stephen K Van Den Eden; Santhi Swaroop Vege; David Bradley; Jose Serrano; Darwin L Conwell Journal: Clin Gastroenterol Hepatol Date: 2021-09-24 Impact factor: 13.576